HomeAI · summaries
Storia in 6 fonti
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
- ·
endpoints.news
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
- ·
thehindubusinessline.com
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer's monthly obesity shot, berobenatide, shows similar side effects to Wegovy, aiming for differentiation in the weight-loss market.
- ·
nationalpost.com
Pfizer bets on weight-loss drugs to power its next decade
Pfizer’s strategy also reflects growing belief among drugmakers obesity eventually may become highly individualized field of medicine.
- ·
New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
- ·
biopharmadive.com
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
- ·
healio.com
Petrelintide, a novel amylin analog, induces 10% weight loss, very well tolerated
NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among adults with obesity or overweight without diabetes,…
- ·
Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
- ·
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.